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1 A term that used to call treatment options for people who are suffering from last stages of chronic kidney 
disease 
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Adapted from: Cohen and Krauss (2003) 








































Adapted from: Wyszewianski (1986) 











Financially catastrophic Not financially catastrophic 
Financial protection No financial protection Financial protection No financial protection 
High cost Inadequate coverage Insufficient ability-to-pay Adequate coverage Sufficient ability-to-pay 
Not high cost Inadequate coverage Insufficient ability-to-pay     













2 According to WHO (2010), the term direct payments cover all forms of out-of-pocket payment and informal payment 
that people pay at the time they use services. Even in a country with universal coverage, people can be required to pay 





























































































































































































































Antiretroviral treatment*  26,000 Yes 
Vertical HIV transmission prevention**  25,000 Yes 
Cardiovascular disease prevention (generic statins)**  82,000 Yes 
Cytomegalovirus retinitis (Gancyclovir)* 185,000 Yes 
Antidiabetic drugs: Pioglitazone compared with Rosiglitazone 211,000 No 
HPV vaccine at age 15 compared with smear test (women aged 35-
65) 
247,000 No 
Osteoporosis: Alendronate compared with Calcium+Vitamin D 296,000 No 




* = compared with palliative care, ** = compared with do nothing 
QALY=quality-adjusted life year, UCS= universal health coverage 
Adapted from: Chaikledklew (2014) 
























Osteoporosis: Residronate compared with Calcium+Vitamin D 328,000 No 
Peritoneal dialysis*  435,000 Yes 
Hemodialysis* 449,000 Yes 
Osteoporosis: Raloxifene compared with Calcium+Vitamin D 634,000 No 
Osteoporosis: Calcitonin compared with Calcium+Vitamin D 1,024,000 No 
































3 Most disease management programmes in the UCS are reimbursed per case, unlike those services in 
outpatient and inpatient departments which are paid by capitation and DRG respectively. 
















2.5 Management of high-cost conditions: disease management and 




























































































Stage Description GFR, mL/min per 1.73m2 Related terms Action* 




- Screening, CKD risk 
reduction 
1 Kidney damage with 
normal or increased GFR 
≤ 90 Albuminuria, proteinuria, 
hematuria 
Diagnosis and 
treatment, treatment of 
comorbid conditions, 
slowing progression, 
CVD risk reduction 
2 Kidney damage with 
increased GFR 
60-89 Albuminuria, proteinuria, 
hematuria 
Estimating progression 
3 Moderate decreased GFR 30-59 Chronic renal 
insufficiency, early renal 
insufficiency, early renal 
insufficiency 
Evaluating and treating 
complications 
4 Severe decreased GFR 15-29 Chronic renal 
insufficiency, early renal 
insufficiency, late renal 
insufficiency, pre-ESRD 
Preparation for RRT 
5 Kidney failure 15 (or need 
dialysis) 
Renal failure, uremia, 
end-stage renal disease 
Kidney replacement 
Adapted from: Levey, Coresh et al. (2003) and The National Kidney Foundation (2002) 
*includes actions from preceding stages. 






4 presence of abnormalities in blood, urine, or imaging studies 
































































































Characteristic CAPD HD 
Frequency everyday 3 times/week 
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Duration per session Every 6 hours  
(APD is performed during bedtime and 
patient is day-dry) 
3½-4½ hours 
Advantage Home-base, less travel cost  
Can be at work while using dialysis 
Patients feel safe when health 
staff manage dialysis  
Disadvantage Need carers to help self-management 
Might cause infection (peritonitis) 
Need to be absent from work to 
undergo dialysis 
Might cause anemia 
Examples of country of 
popularity 
Mexico, Hong Kong  USA, China, Japan  
Source: Nesrallah, Blake et al. (2005)  
CAPD=continuous ambulatory peritoneal dialysis, APD=automated peritoneal dialysis, HD=hemodialysis, both 
CAPD and HD are the most popular modalities in Thailand and are available for the UCS’s members 














































































































































































































2.8 Cost of RRT in literature  































Authors Setting Data sources Forecast for Method used Forecast years 
Quinn, Laupacis et 
al. (2009) 
Canada 1999-2005: 
1) Billing claims in the Ontario Health Insurance Plan database 
for identifying numbers of dialysis patients 
2) Registered Persons Database for demographic and vital 
status information and determining the eligibility for the benefit 
coverage    
3) Hospitalisations and kidney transplantation from Canadian 
Institute for Health Information Discharge Abstracts Database 
Incidence and prevalence of 
chronic and acute dialysis patients 
Exponential smoothing model, 
ARIMA model, stepwise auto-




Prakongsai et al. 
(2006) 
Thailand 1) United States Renal Data System annual report 2004 
2) National Renal Registry of Malaysian Society of Nephrology 
2004 
3) Thailand Renal Replacement Therapy Registry report 1997-
2000 
Dialysis and kidney transplant 
costs to the Universal Coverage 
Scheme  
Estimations of unit costs of various 
activities multiplied by expected 
numbers of patients 
1st year to 16th  
year 




Patient data from 3 public hospitals, 1996-2000  Numbers of hemodialysis 
treatments 
ARIMA model 2001-2005 
Xue, Ma et al. 
(2001) 
USA United States Renal Data System annual report 1982-1997  
 
Incidence and prevalence of ESRD 
patients, dialysis patients, 
functioning transplants, and waitlist 
patients 
Stepwise auto regressive model 1998-2010 
Schaubel, 
Morrison et al. 
(1998) 
Canada Demographic data, clinical history data, and deaths from the 
Canadian Organ Replacement Register, 1981-1994 
Numbers of ESRD patients by 
each RRT modality 




1) Population profile from Institute of Population Problems 
2) Annual Reports on Dialysis Therapy in Japan and vital 
statistics in Japan 
3) Renal transplants from Japanese Society for Transplantation 
Numbers of ESRD patients System dynamics model 1980-2000 
Note: ESRD= end-stage renal disease, ARIMA=auto-regressive integrated moving average, *costs of treatment during the studied period were estimated but not projected to the future 
















2.9 Renal replacement therapy of the UCS  





































































































Meechai(2002)     Tisayaticom(2003)1/    Thanatchon(2012) 
KT 
Suksamran(2012) 
Labour costs % 25 32 34, 47, 40 18 18 
Material costs % 74 42 46, 41, 43 60 79 
Capital costs % 1 24 21, 12, 17 13 3 
Indirect costs % N/A 19 N/A 9 N/A 
Unit cost (Baht)2/ 45,755 2,328-4,068 1,927, 1,525, 1,708 3,288 388,327 
    PD=peritoneal dialysis, HD= hemodialysis, KT =kidney transplant 
    1/ Public, private, and both public and private facilities 
    2/ Per PD patientyear, or per HD session, or per transplantation 
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supports the physician or practitioner/patient relationship and plan of care; 
emphasizes prevention of exacerbations and complications through the use of evidence-based practice 
guidelines and patient empowerment strategies; and evaluates clinical, humanistic, and economic outcomes 
on an ongoing basis with the goal of improving overall health. 
Disease management components include: 
 population identification processes; 
 evidence-based practice guidelines; 
 collaborative practice models to include physician and support-service providers; 
 patient self-management education (may include primary prevention, behavior modification 
programs, and compliance/surveillance); 
 process and outcomes measurement, evaluation, and management; and routine reporting/feedback 
loop (may include communication with patient, physician, health plan, and ancillary providers, and 
practice profiling). 
*Full-service disease management programs must include all 6 components. Programs consisting of fewer 
components are disease management support services 








3.3 Review questions 
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3.5.1 Disease management arrangements at the policy level 





































































































N/A Earmarked at 1% of total  
health care budgets at the 
beginning of nationwide 
implementation period 
(2004-2006)  
Registering members Global budget based on the 
number of registered patients 
with adjusted weight  
Additional compensation for 
a registered patient 
Providing services Additional pay-for-
performance payment for 
targeted outcomes 
Additional flat rate payment 
for documentation, patient 
education  





























































3.5.2 Disease management at provider-patient level: results from 
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Author Setting Study design Comparison strategy Diseases DM interventions Study’s Measures Effects 




study of general 
practioners 









Policy level: reforms of the primary 
health care to introduce team practice of 
GPs. Each GP is paid  extra for each 
patient on top of the capitation. 
Provider level: clinical practice 
guidelines and organizing workshops of 
the GP team for assessment of care 
quality and appropriate prescribing 
Proportions of patients 
receiving appropriate 
care 
In terms of quality of care, 
results were mixed and 
inconclusive. 
Agrinier, Altieri et 
al. (2013) 
Lorraine, France Descriptive and 
time-series study 
of patients 




HF Policy level: no detail specified 
Provider level: home-nurse visits and 
patient/family education 
Number of HF 
hospitalizations and 
difference of total cost of 
operating the DMP and 
the costs saved by the 
avoided hospitalizations 
In 2010, there was a 7.19% 
reduction in the risk of 
hospitalization in the region, 
estimated net savings 
associated with the DMP 
was €1,927,648. 
Campbell, 
Ronksley et al. 
(2012) 
Alberta, Canada Population-based 
cohort analysis of 
patients aged < 





Diabetes Policy level: primary care reform by 
establishing Primary Care Networks 
funded on a capitated basis to support 
health services that fall outside the fee-
for-service payment. 
Provider level: multidisciplinary teams 
and enhancing patient education as a 
basic 
Hospital admissions, 




Receiving care in a primary 
care network was associated 
with significantly lower rates 
of all measures and the 
effects were similar across 
each population group. The 
study noted a marked risk of 
higher hospital admissions 
and emergency visits of 
lower income and 
indigenous groups. 
Humphreys, 
Harvey et al. (2012) 
Primary care 
trusts in Greater 
Manchester 
Descriptive study 





Policy level: payment for initiating a 
DPM, attending training sessions, and 
Number of registered 
patients and level of 
Percentage of improvement 
of both indicators were 
observed but level of 
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Author Setting Study design Comparison strategy Diseases DM interventions Study’s Measures Effects 
region, UK CKD  final payment at the end of the DMP. 
Provider level: NICE guidelines on the 
identification and management of CKD, 
staff training 
blood pressure achievement varied across 
providers   
 
Coburn, 






















Policy level: Medicare’s FFS coverage 
and additional fixed negotiated fee per 
participant per month 
Provider level: Patient education, 
coordination mechanism, guideline use 




Nurse care management 
associated with reduction of 
all-cause mortality in 
chronically ill elderly  





survey of a DMP  
Control group: 
usual care 
Diabetes Policy level: regulate responsibilities of 
doctors, patients, and social health 
insurance companies, as well as set up 
their treatment goals.  
Provider level: define eligible patients 
and regular follow-up, provide health 
education to patients and health care 
providers, coordination of complex 
medical care, and other support 
Patient’s self-care 
management, body 
examination, and other 
laboratory tests for 
diabetes 
In comparison to the usual 
care group, patients in DMP 
were more likely to received 
anti-diabetic medications, 
more frequent medical 
examination, diabetes 
educations, and achieve 
blood pressure goals. Both 
groups had satisfactory 
HbA1c but poor low-density 
lipoprotein levels. 
Meng, Wamsley et 
al. (2010) 
Medicare patients 
in New York, 
West Virginia and 





Disability Policy level: no detail specified 
Provider level: patient education, 
individualised health promotion and 
Body mass index and 
dependence in Activities 
of Daily Living 
DM interventions were 
statistically associated with 
less worsening in disability of 
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Author Setting Study design Comparison strategy Diseases DM interventions Study’s Measures Effects 
Ohio, USA programme disease self-management coaching, 
medication management, and physician 
care management. 
participants in normal weight 
group, but not in 
underweight, overweight, 
and obese groups 










Asthma Policy level: DMPs were introduced by 
the Act to Reform the Risk Structure 
Compensation Scheme in Statutory 
Health Insurance (SHI). Sickness funds 
received higher payments if they set up 
certified DMPs and motivated patients to 
enroll.  
Provider level: The Act provides 
recommendations on how to conduct a 
DMP and its preferred components. 
% of hospitalisation, risk 
to hospitalisation, and a 
set of prescription drugs 
for asthma 
Effects of DMP on patients’ 
outcomes were weak, no 
statistical difference 
observed on hospitalization 
or high risk for future 
emergency care. However, 
the DMP group had more 
statistically significant 
numbers of patients with 
prescriptions of 
corticosteroid inhalers which 
these drugs are 
recommending in the asthma 
guideline. 












Policy level: Indiana Office of Medicaid 
Policy and Planning (OMPP) introduced 
the Indiana Chronic Disease 
Management Program to eligible 
Medicaid participants with diabetes 
and/or CHF. The OMPP is also 
responsible for hiring and training of 
personnel, and coordination of 
physicians and eligible Medicaid 
members.  
Provider level: nurse care management, 
clinical guidelines for physicians, 
Costs of paid claims Claim data showed slight 
improvements in cost control 
but results were statistically 
significant only in some 
sectors and regions. 
CHAPTER 3  Evidence on Disease Management Programmes: results from population-based studies 
76 
	
Author Setting Study design Comparison strategy Diseases DM interventions Study’s Measures Effects 
collaborative groups for primary care 
practice. An individual patient’s risk was 
assessed for predicting annual health 
care claims. 
Gapp, Schweikert 






study of insured 
patients with a 




AMI Policy level: Sickness funds are 
obligated to provide and evaluate DMP. 
They receive higher payment for a DMP 
enrollee.  
Provider level: patient education, 
programme review and assessment 
Quality of services 
(medications and 
counseling) 
The study was unable to 
conclude major health 
outcomes. Findings 
suggested no statistical 
differences in quality of life 
and body mass index, and 
only a minor reduction in 
smoking. 























Policy level: Medicaid FFS, no detail 
specified 
Provider level: monitoring, assessments, 
and interventions for patient self-
management by trained physicians and 
pharmacists. 
HRQoL questionnaire, 
medical utilization, drug 
utilization, adverse drug 
events and cost of 
average amount paid 
per member per month 
There were reductions in 
costs, utilisation, and 
adverse drug reaction 
among patients receiving 
interventions but results 
were inconsistent across all 
disease groups, especially in 
patients with co-morbidity 








Dementia Policy level: no detail specified 
Provider level: collaborative care 
planning with carers, carer’s self-
management support, ongoing follow-
up, and provider education 
Physicians’ adherence 
to clinical guideline, 
obtaining community 
services/resources, and 
patients and carers’ 
health and quality-of-
care measures 
Participants in DMP group 
had higher scores of most 
measurers than the usual 
care group except HRQoL of 
carers which were 
comparable between the two 
groups. 
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Author Setting Study design Comparison strategy Diseases DM interventions Study’s Measures Effects 
Gilmer, Philis-
Tsimikas et al. 
(2005) 
San Diego 
County, CA, USA 
Non experimental  







Diabetes Policy level: County Medical Services 
contracted with Project Dulce to provide 
diabetes DMP for  adults 
Provider level: trained nurse and other 
diabetes related health worker to use 
guideline protocols, patients’ self-care 
management, and trained peer 
educators recruited from the patient 
population to provide the training 
programme 
Diabetes related 
laboratory tests and 
project management 
costs 
The intervention group was 
related to significant 
improvements in HbA1c, 
both systolic and diastolic 
blood pressure, total 
cholesterol, and LDL-C. 
Expenditures for medicine 
and DMP arrangements 
increased. There was 
probability of reductions in 
hospitalisation costs within 
the first year after 
implementation. 














Policy level: no detail specified 
Provider level: patient education for self-
care management, patient health 
assessment, physician education, 
medication review, and coordination with 
community service   
SF-36, satisfaction, paid 
claim costs, utilization, 
and mortality 
Except for satisfaction that 
favoured the intervention 
group, most results from 
intervention and control 
groups showed difference 
but not statistically 
significant. Health care costs 
rose considerably in both 
groups but not statistically 
significant difference. 
AMI= acute myocardial infarction, BP=blood pressure, CHD=coronary heart disease, CHF= congestive heart failure, CKD=chronic kidney disease, COPD=chronic obstructive pulmonary disease, DMP=disease 
management programme, FFS=fee-for-service, GERD=Gastro-esophageal reflux disease, HF=heart failure, HMO=Health Maintenance Organization, HRQoL=health-related quality of life, HT=Hypertension, 
IHD=ischemic heart disease, PUD=peptic ulcer disease, RCT=Randomised controlled trial, SF-36=Short form health survey
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4.4.1 Objective 1: The rationale behind and the application of the disease 
management approach in the RRT programme 
Method of objective 1: qualitative approaches of document review, semi-































technique.    




























































































































               No. RRT unit4/ 
           HD                     PD 
Phitsanulok 858,988 3.0 27,490 7 2 
Kampangpet 729,522 3.3 22,083 2 1 
The whole kingdom 65,124,716 3.2 25,194 533 102 
*Average monthly income per household in Thai Baht, based on the Household Socio - Economic Survey 
Source: 1/National Statistic Office (2014) available from 
 :http://service.nso.go.th/nso/nso_center/project/search_center/23project-th.htm 
2/National Statistic Office (2010) available from: http://popcensus.nso.go.th/upload/popcensus-08-08-55-E.pdf  
3/National Statistical Office (2010) available from:http://service.nso.go.th/nso/web/statseries/statseries11.html 
4/Thai RRT report (2012) available from: http://www.nephrothai.org/trt/trt.asp?type=TRT&news_id=418 



































ESRD=end-stage renal disease, RRT=renal replacement therapy, PD=peritoneal dialysis	





























1. Perception of high-
cost diseases 
What kind of diseases/conditions 
that can cause a burden on 
patients when paying for health 
care costs? Have you ever 
experienced this issue and what 
was your response? 
     
2. Purpose of the  RRT 
programme 
Why ESRD is selected to be 
managed separately? 
How to select a disease/condition 




    
3. Design of the RRT 
programme 
Why disease management and  
the PD-first are used?	      
4. Process of the RRT 
programme 
What is the patients’ journey? 
How about 
• patient selection 
• patient self-care education 











5. (For patients only) 
decision making 
Who made decision about getting 
in the programme? If chose not to 
get in, why? 
     
6. (For patients only) 
care costs and quality 
of life 
Do you have to pay anything to 
receive dialysis? 
How is quality of your life at the 
moment? 
     
 
 
7. Links between RRT 
programme and other 
components 
What are linkages between levels 
of care and within the health 
system? 
How do they work together? 




After the programme started, what 
has been changed in your 
perception/experience? 
What are concerns of the 
programme in the future? 
What is the perceived success of 
the programme? 



































































































7Within a three-month period, a new patient is expected to be keen enough to independently perform PD. 
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4.4.1.7 Research ethics 
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4.4.2 Objective 2: The changing patterns of access to service and 
mortality of ESRD patients overtime 
Method of objective 2: Age-period-cohort analysis based on administrative 
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8 The ICD10 code for ESRD stage 5 was changed to N185 in April 2012. 
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ii. Age-period-cohort analysis 
The	general	form	of	the	age‐period‐cohort	model	for	rates	(a,	p)	is:	
















































4.4.3 Objective 3  Long term projections of RRT population and 
payments of the RRT programme 
Method of objective 3: cost modelling and time-series projection of RRT 
population 
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 PD1/  HD2/ KT3/  
Material costs 74 43 79 
Labour costs   25 40 18 
Capital costs 1 13 3 
PD=peritoneal dialysis, HD= hemodialysis, KT =kidney transplant 
1/ Laonapaporn, Punthunane et al. (2014) 
2/ Tisayaticom, Patcharanarumol et al. (2003) 
3/ Suksamran, Kongsin et al. (2012) 
The	researcher	used	these	figures	to	calculate	the	unit	cost	per	patient‐year	
composed	of	the	three	main	cost	objects:	material,	labour,	and	capital.	
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Objective Method Measures Source of data 
1. Describe the rationale 
behind and the application of 
the disease management 
approach in the RRT 
programme 
Qualitative approaches: 
1) document review, 2) 
semi-structured 
interview, 3) focus 
group discussion, and 
4) observation	
Responses of payers, 
providers, and patients 
to the RRT programme 
and effects of the 
programme on them 
Various archival 
documents, 41 
interviews, 1 focus group 
discussion, and 10 
observations 
2. Explore the changing 
patterns of access to service 
and mortality of ESRD 





Access to RRT services 
and mortality of ESRD 
and RRT patients 
NHSO’s administrative 
data and vital registry 
 
3. Undertake long term 
projections of the number of 
patients and budget needs for 
the RRT programme 
Cost modelling and 
time-series projection of 
the RRT population   
Long term costs, number 
of patients, and RRT 
programme cost drivers 
NHSO’s administrative 
data 
NHSO=National Health Security Office, ESRD=end-stage renal disease, RRT=renal replacement therapy 
4.6 Limitations 
4.6.1 Data sources 
Data	obtained	in	this	study	came	from	both	primary	and	secondary	sources.	
Primary	data	were	collected	from	interviews,	a	focus	group	discussion,	and	
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5.2 Renal replacement therapy of the UCS  




















5.2.2 Features of the RRT programme 





































9 In this case, the NHSO supports the cost for EPO to prevent anemia in patients receiving HD. 
10 These patients had to pay copayment approximately £11 per session, but this rule was abolished in 2012. 







































 RRT=renal replacement therapy, CAPD=continuous ambulatory peritoneal dialysis, HD=hemodialysis,  
GPO=Government Pharmaceutical Organization, CHI=Central office for Health care Information 


















































CKD=chronic kidney disease, CAPD or PD=continuous ambulatory peritoneal dialysis, HD=hemodialysis, KT=kidney 
transplant, RRT=renal replacement therapy 



















Type of document         Information selected 
NHSO board meeting minutes • RRT benefit 
NHSO’s RRT manual for providers • UCS’s RRT protocol 
• Payment system and reimbursements 
NHSO’s M&E reports • Indicators on the RRT programme 
• Numbers of registered patients  
National Health Security Act B.E. 2545 (2002) • Budget allocation of the NHSO 
Clinical guidelines • Guidelines on caring patients with CKD  
• PD’s self-care management 
Newspaper clippings • Kidney patient protests 
• RRT benefit 
• Interviews of key persons 
Research reports • Incidence and prevalence of ESRD in Thailand 
• Numbers of RRT human resources and facilities 
Research articles • Access to RRT 
• RRT benefits 






















Characteristics Policy maker Provider	
Gender 
• Male 







Years of experience* 5-30 years 3-15 years 
Background or occupation 
• Physician 
       Nurse 









Total number 9 people 10 people 
* in the current position 




















Mode Gender Age Education Started RRT Household size Job at present 
Economic 
status1/ 





















Male (4) 36-70 P (1) 
S (3) 
2006-2014 1-8 people None (3) 
Occasional job (1) 
Poorer (1) 
Middle (3) 














Male (2) 57,70 P (2) 2006,2012 2,6 people None (1) 
Occasional job (1) 
Poorer (2) 
 
KT Male (1) 
Female (1) 
40,52 S,B 2003,20072/ N/A Full time job (2) Richer (2) 
OO Female (2) 64,75 P (2) 2010,20123/ 2 people None, farmer Poorer (2) 




PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant, OO=opt-out; 
P=none or primary school, S= secondary school, B=bachelor’s degree or higher; 
1/as judged by investigators, 2/year having kidney transplant, 3/year diagnosed with ESRD 
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5.4.1 Views on high-cost, catastrophic diseases perceived by 


























































11 Approximately 10 pounds 
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5.4.1.3 Policy makers 
The	 policy	 makers’	 attention	 was	 focused	 on	 access	 to	 care	 and	 equity.	
Providing	 access	 to	 essential	 healthcare	 and	 preventing	 beneficiaries	 from	
financial	 catastrophe	 due	 to	 high	 cost	 health	 care	 are	 NHSO’s	 goals.	 As	 an	
interviewee	stated:	




In	 terms	 of	 high‐cost	 conditions,	 the	 NHSO	 used	 criteria	 to	 distinguish	 these	
conditions	from	others.	First	they	looked	for	treatments	that	were	not	available	
in	 the	benefit	package.	Next,	 the	 focus	was	put	on	health	problems	with	new,	
expensive	treatments,	which	meant	they	were	most	likely	to	be	inaccessible.	For	
high‐cost	 treatments,	 policy	makers	 believed	 that	 it	was	 essential	 to	 set	 up	 a	
special	arrangement	 in	order	 to	 increase	access	 to	care.	This	was	because	 the	
closed‐end	payments	of	the	NHSO	discouraged	providers	from	providing	high‐
cost	treatments.	As	an	interviewee	from	the	NHSO	explained:	
“We	 think	 patients	 can’t	 use	 these	 services	 because	 there	 are	 gaps	
between	 the	policy	and	providing	health	 services.	 […]	This	 is	why	 these	


































































12 Pinij Jarusombat was in the position between October 2005 and September 2006 
13 Dr Mongkol Na Songkla was appointed to be the minister between October 2006 and February 2008 




From a small society of kidney patients formally established in 2006, the Society has now expanded to 
more than 40,000 members. This figure covers just beneficiaries of the UCS, many more members are in 
the other two public health insurance schemes: Social Security Scheme and Civil Servant Medical Benefit 
Scheme. Its members are the patients who suffer from the last stage of kidney disease, carers, and people 
who are at risk of kidney disease.
Going back ten years, the Friends of Kidney Patient Society was set up by Subin Noksakun, known as 
Uncle Subin, the first chairman of the society and the champion of kidney patients’ rights. Subin once 
belonged to a rich family. He had a family business, properties, and savings of more than 10 million Baht: 
but most of it is gone due to 20 years of treatment for his kidney disease. At the time he gave the interview, 
just a house and a few hundred Baht savings were left. Chronic kidney disease ran in Subin’s family, as his 
elder brother and son also suffered from the condition. One day Subin went to receive his treatment as 
usual, he listened to old, repeated conversations on how to control body weight and salt intake and felt that 
there was no improvement in benefits for kidney patients. He had once acted as a member in the 
Employee Labour Congress, and this inspired Subin to do something so that kidney patients would not 
face financial catastrophe like him. 
With support from several networks such as the NHSO and other patient groups for cancer, heart disease, 
and HIV/AIDS sufferers, the Friends of Kidney Patient Society was set up. After several visits and talks 
with politicians, and together with the movement of academicians/policy makers, the RRT was included in 
the health benefit of the UCS, starting in January 2008. From this success, the group moved to call for 
expanding the RRT benefit to those who had developed ESRD before they became members of the Social 
Security Scheme. The success took two years to achieve, and is indebted to  Subin’s significant effort. He 
once mentioned, “When I do the visit, I go alone. Other members are not allowed to come along, otherwise 
they can’t earn money for their dialyses. I don’t have much too but I have no choice. My daughter asked ‘Is 
it better to just stay home?’ But I can’t. I haven’t got much time left so I have to do something worthwhile. 
Can Thailand have decent health benefits like those developed countries? The answer is ‘Yes, we can’ but 
there needs to be someone to start it.” 
According to the Director of AIDS Access Foundation, “Before the establishment of the Friends of Kidney 
Patients Society, kidney patients did not gather into groups and there was no existing relationship between 
kidney patients and other patient groups. Because of the movement since Subin coming in and Dr 
Sanguan’s (NHSO’s first secretary general) intention to help kidney patients, the establishment of the RRT 
benefit succeeded in a short amount of time, less than a year. Compare that to the HIV/AIDS benefit, 
where we spent almost ten years.” 
Subin passed away at the age of 62 on 6th May 2012, six months after the death of his son. Now the 
Friends of Kidney Patients Society has a new chairman and has been contributing to many activities; 
building up knowledge of self-care management to patients and carers, and also movements for public 
participation. The society has its branches in every province across the country, where the core members 
run monthly visits and set up forums in order to expand the network and develop collective approaches, 
such as building up knowledge and friendship support groups, and how to fundraise for spending on 
various activities. Besides the effort to put RRT in the health benefit basket and improve the benefit 
thereafter, the group, with its networks, also plays important roles in a number of actions to assure equal 
opportunities in society. For example, they called for the abolition of the rule prohibiting patients with 
chronic kidney disease and tuberculosis from positions in the civil service in 2009. Recently, in 2015, they 
gathered to request that the minister of the Ministry of Public Health reconsider the changes in the NHSO’s 
budget allocation and the introduction of patient charges/ co-payment under the UCS.  
- Based on interviews and archival sources (Manager Online, 26 December 2006; Consumerthai, 12 
February 2009; Bangkokbiznews,19 May 2012; NHSO newsletter, July 2013; Matichon, 3 February 2015
	
































14 acting as the Prime Minister during 2006-2008 
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15 A humanitarian organisation for kidney patients, patronised by Her Royal Highness Princess Galyani Vadhana 

























































5.4.3.1 System’s resources, policies, and delivery system design 






16 including trained kidney doctors from other subspecialties including internists and pediatricians 








 2006 2007 2008 2009 2010 2011 2012 
PD centres 57 61 105 120 139 144 178 
HD centres 399 395 428 440 447 497 533 
















































Protocols for providers are developed from evidence-based-
guidelines and linked to the payment system 
Population  identification Secondary prevention programme to identify patients with CKD 
risk factors. Patients are referred to a nephrologist if they reach 
advanced stages of CKD 
Reporting system  Electronic reporting system to manage the care process: 
registration, service delivery, medications that link to the 
payment system 
Process & outcome measurement National level: indicators such as number of patients in the 
programme, survival rate, and  PD-related infection rate 
Facility level: may vary 
Collaborative practice Dialysis nurses act as a case manager or central person to 




communicate with patients and nephrologists. Patients may be 
referred to other professionals upon nephrologists’ requests. 
Self-care management support All patients are taught to perform self-care PD, as well as 
monitoring their clinical conditions, medicines and dietary intakes 
CKD= chronic kidney disease, PD= peritoneal dialysis 













































“In	 this	 first	period,	 separating	 the	administration	of	RRT	 from	normal	
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Behaviour % compliance 
1) Arranging equipment 80 
2) Hand washing 70 
3) Surface cleaning 80 
4) Checking the unused bag 90 
5) Combining and connecting exchange devices 100 
6) Weighing of used dialysis solution 90 
7) Updating health records 90 
8) Waste disposal 100 
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            Societal movement            Political involvement 
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CHAPTER 6 The changing patterns of access to service and 
































UCS=Universal Coverage Scheme, RRT=renal replacement therapy, PD=peritoneal dialysis, HD=hemodialysis, 
KT=kidney transplant, death=all-cause of death  























Model 1. Entry into the RRT programme 2. Mortality 
Follow-up 
period  
Jan 2008 – Dec 2013 Overall ESRD mortality: Jan 2005 - Dec 
2013  
CFR and RRT mortality: Jan 2008-Dec 
2013 
Measure ESRD patients who have 
experienced dialysis registration or 
kidney transplant  
ESRD patients who died due to any 
cause or patients who died on RRT  
Numerator Number of new registrations or 
transplantation 
Number of deaths 
Denominator New ESRD diagnoses of UCS Mortality of ESRD patients: mid-year UCS 
population 
Case fatality: UCS patients with ESRD 
diagnosis 
RRT mortality: UCS patients who used 
RRT 
Variable: Age Number of years between the year of 
birth and registration with the RRT 
programme (or transplantation)  
Range: 20-89 years (dialysis) 
           :   20-60 years (KT) 
Number of years between the year of birth 
and the year of death 
Range:  20-89 years 
Variable: Period Calendar year of registration or 
transplantation 
Range: 2008-2013 
Calendar year of death  
Range: 2005-2013 or 2008-2013 
Variable: Cohort Calendar year of birth  
Range: 1908-1993 
Calendar year of birth  
Range: 1905-1993 
Covariates HD, PD, and KT  None 
UCS=universal coverage scheme, ESRD=end-stage renal disease, CFR=case facility rate, RRT=renal 
replacement therapy, HD=hemodialysis, PD=peritoneal dialysis, KT=kidney transplant 
The	data	analysis	involved	three	main	steps;	1)	constructing	main	dataset,	2)	
descriptive	analysis,	and	3)	age‐period‐cohort	analysis.	


















1 ++GlXQAecEU+pRH01JSPEg== . 2011 . 2013 None 
2 ++GlXQAecEU3g9P0Vpp5ow== . 2009 . . None 
3 ++GlXQAecEUbnKTSWrSB+w== . 2008 . . None 
4 ++GlXQAecEUvA3rv2+ZMyA== 02-Sep-64 2011 2011 2012 PD 
5 ++GlXQAecEV2J/Jw/D9uJw== 25-Sep-63 2013 2014 . PD 
6 ++GlXQAecEV7qhDaldT8xg== . 2012 . 2013 None 
7 ++GlXQAecEVDUCjKc6qO/Q== . 2004 . 2005 None 
8 ++GlXQAecEVMHvANBIlfCA== . 2011 . 2012 None 
9 ++GlXQAecEVN4i514t1G2g== 09-Mar-45 2008 2011 2011 HD 














1 20 1988 2008 35-39 1986-90 2008 13 51 
2 21 1987 2008 20-24 1986-90 2008 12 73 
3 22 1986 2008 20-24 1986-90 2008 8 71 
4 23 1985 2008 20-24 1981-85 2008 8 70 
5 24 1984 2008 20-24 1981-85 2008 11 94 
6 25 1983 2008 25-30 1981-85 2008 14 71 
7 26 1982 2008 25-30 1981-85 2008 11 112 
8 27 1981 2008 25-30 1981-85 2008 17 107 
9 28 1980 2008 25-30 1976-80 2008 16 126 
10 29 1979 2008 25-30 1976-80 2008 16 128 
Age=age at death, Cohort=calendar year of birth, Period=year of death, death counts=number of deaths in a particular 
group, population=number of patients in a particular group 
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6.2.3 Descriptive analysis 
The	descriptive	analysis	is	presented	in	two	sections	for	the	two	main	models:	
entry	into	the	RRT	programme	model,	and	a	mortality	model.	





































ESRD death rate   =    Number of deaths from all causes among patients with ESRD x 100,000 










CFR	 =						 Number of deaths from all causes among patients with ESRD x 100 
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RRT mortality rate  			=		   Number of deaths from all causes among patients on RRT x 1,000 
                 Number of all patients on RRT 
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Age 2008 2009 2010 2011 2012 2013 %Total 
20-24  63   94   80   104   132   113  2.17% 
25-29  66   130   106   129   138   121  2.55% 
30-34  94   144   179   155   167   201  3.37% 
35-39  101   201   208   251   247   259  4.56% 
40-44  150   315   330   346   412   460  7.15% 
45-49  185   428   498   571   608   641  10.42% 
50-54  196   518   639   729   813   838  13.36% 
55-59  201   557   734   837   955   1,078  15.67% 
60-64  118   506   699   839   992   1,101  15.58% 
65-69  76   362   495   636   726   838  11.58% 
70-74  42   196   362   399   476   555  7.61% 
75-79  18   103   148   216   225   304  3.93% 
80-84  7   33   48   80   91   90  1.50% 
85-89  -    7   15   22   18   21  0.54% 








Age 2008 2009 2010 2011 2012 2013 %Total 
20-24  141   141   141   141   141   141  4.44% 
25-29  161   29   65   69   58   51  2.27% 
30-34  206   45   88   86   87   75  3.08% 
35-39  288   52   99   127   110   129  4.22% 
40-44  403   81   163   177   148   142  5.85% 
45-49  534   90   205   264   267   219  8.29% 
50-54  788   110   280   336   316   308  11.22% 
55-59  874   150   343   433   426   445  14.02% 
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Age 2008 2009 2010 2011 2012 2013 %Total 
60-64  901   134   386   482   465   469  14.89% 
65-69  893   97   287   364   374   313  12.22% 
70-74  725   73   252   319   275   265  10.02% 
75-79  434   37   132   199   182   146  5.93% 
80-84  194   12   69   87   101   57  2.73% 
85-89  58   4   22   27   33   14  0.83% 






Age 2008 2009 2010 2011 2012 2013 %Total 
20-24 9 9 17 39 31 18 12.40% 
25-29 6 17 16 19 33 21 11.29% 
30-34 13 12 17 34 37 28 14.21% 
35-39 15 20 16 37 37 22 14.82% 
40-44 15 9 20 17 33 32 12.70% 
45-49 12 24 11 19 35 26 12.80% 
50-54 11 11 22 12 27 27 11.09% 
55-59 12 12 14 25 11 20 9.48% 
60-64 0 0 4 0 3 5 1.21% 









Age 2008 2009 2010 2011 2012 2013 
20-24 418 (1.2%) 168 (1.1%) 284 (0.8%) 360 (1.1%) 293 (0.9%) 174 (0.9%) 
25-29 638 (1.8%) 285 (1.9%) 400 (1.2%) 474 (1.4%) 377 (1.2%) 218 (1.1%) 
30-34 970 (2.8%) 411 (2.7%) 612 (1.8%) 689 (2.0%) 535 (1.7%) 329 (1.6%) 
35-39 1257 (3.6%) 511 (3.4%) 771 (2.3%) 936 (2.7%) 795 (2.5%) 481 (2.4%) 
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Age 2008 2009 2010 2011 2012 2013 
40-44 1825 (5.2%) 769 (5.1%) 1206 (3.5%) 1392 (4.1%) 1185 (3.7%) 802 (4.0%) 
45-49 2549 (7.2%) 1084 (7.2%) 1804 (5.3%) 2210 (6.5%) 1828 (5.7%) 1208 (6.0%) 
50-54 3677 (10.5%) 1410 (9.4%) 2663 (7.8%) 2995 (8.8%) 2688 (8.4%) 1719 (8.5%) 
55-59 4392 (12.5%) 1811 (12.1%) 3339 (9.8%) 3841 (11.3%) 3680 (11.5%) 2425 (11.9%) 
60-64 4407 (12.5%) 1904 (12.7%) 3830 (11.2%) 4509 (13.2%) 4326 (13.5%) 2849 (14.0%) 
65-69 4613 (13.1%) 1943 (13.0%) 3741 (11.0%) 4394 (12.9%) 4274 (13.3%) 2758 (13.6%) 
70-74 4555 (12.9%) 1872 (12.5%) 3919 (11.5%) 4632 (13.6%) 4460 (13.9%) 2577 (12.7%) 
75-79 3448 (9.8%) 1553 (10.4%) 3320 (9.7%) 4054 (11.9%) 3782 (11.8%) 2388 (11.8%) 
80-84 1776 (5.0%) 863 (5.8%) 2017 (5.9%) 2507 (7.4%) 2650 (8.3%) 1635 (8.1%) 
85-89 661 (1.9%) 419 (2.8%) 872 (2.6%) 1113 (3.3%) 1207 (3.8%) 733 (3.6%) 
Total 35,186 (100%) 15,003 (100%) 28,778 (100%) 34,106 (100%) 32,080 (100%) 20,296 (100%) 


























































































































































































































































































































































































































































































































































 Model Effect Da/ Residual df Db/ p-value 
PD Age Reference 2713.9 539 Reference  
 Age-drift |Ac/ 2659.7 538 54.127 <0.001 
 Age-Cohort C|Ad/ 2612.2 534 47.535 <0.001 
 Age-Period-Cohort P|A,Ce/ 2416.8 530 195.357 <0.001 
 Age-Period C|A,Cf/ 2469.2 534 -52.409 <0.001 
 Age-drift C|Ag/ 2659.7 538 -190.483 <0.001 
HD Age Reference 25537 542 Reference  
 Age-drift |Ac/ 21934.1 541 3602.9 <0.001 
 Age-Cohort C|Ad/ 21922.3 537 11.9 0.018 
 Age-Period-Cohort P|A,Ce/ 7011.3 533 14911 <0.001 
 Age-Period C|A,Cf/ 7027.6 537 -16.3 0.002 
 Age-drift C|Ag/ -14906.6 541 -14906.6 <0.001 
a/ Residual deviance 
b/ Increase in residual deviance from the next upper model   
c/ Linear effect of cohort or period adjusted for age 
d/ Non-linear cohort effect adjusted for age 
e/ Non-linear period effect adjusted for age and cohort 
f/ Non-linear cohort effect adjusted for age and period  
g/ Non-linear period effect adjusted for age	






































HD= hemodialysis, PD=peritoneal dialysis, KT=kidney transplant  
Note: Figures a, c, and e show estimated rates by age of (a) peritoneal dialysis: PD, (c) hemodialysis: HD, and (e) 
transplantation: KT. Rate ratios in Figures b, d, and f compare new registration rates of PD (b), HD (d), and 
transplantation rates (f) in a particular year and the rate in the reference year (2010). Shaded areas are 95% 
confidence intervals 
6.3.2 ESRD mortality 







































Calendar year of registration
 




































Calendar year of registration
 





































Calendar year of transplant
 
f. Rate ratios relative to the reference year










Age 2005 2006 2007 2008 2009 2010 2011 2012 2013 %Total 
20-24 49 42 46 52 48 57 60 41 48 0.59 
25-29 44 60 70 74 86 69 78 84 65 0.84 
30-34 73 81 107 93 100 123 114 119 101 1.21 
35-39 103 125 157 149 167 179 185 181 154 1.86 
40-44 152 208 261 292 301 313 345 358 242 3.29 
45-49 189 297 387 419 487 512 556 593 449 5.18 
50-54 272 378 577 725 745 838 937 964 776 8.27 
55-59 286 451 644 830 1066 1187 1313 1365 1074 10.94 
60-64 281 469 627 846 1171 1450 1707 1753 1368 12.87 
65-69 351 512 681 908 1297 1598 1729 1921 1590 14.09 
70-74 276 434 639 891 1347 1743 2032 2146 1642 14.84 
75-79 171 288 468 663 1139 1545 2005 2094 1510 13.15 
80-84 73 134 246 370 647 1058 1350 1532 1163 8.75 
85-89 33 76 92 166 323 439 607 785 572 4.12 
Total 2,658 3,588 5,045 6,419 8,587 10,716 12,478 12,811 10,754    100.00 
Table 6‐10  UCS population aged 20‐89, 2005‐2013 
Age 2005 2006 2007 2008 2009 2010 2011 2012 2013 %Total 
20-24 3,091,952 3,081,401 3,006,693 2,954,843 3,063,563 3,130,619 3,237,013 3,361,135 3,423,030 10.02 
25-29 2,867,485 2,801,673 2,637,599 2,581,614 2,582,281 2,580,171 2,505,985 2,620,408 2,550,342 8.39 
30-34 3,497,324 3,371,738 3,235,964 3,117,867 3,032,949 2,955,463 2,777,820 2,874,706 2,828,223 9.79 
35-39 3,871,765 3,846,779 3,760,168 3,657,674 3,602,595 3,538,083 3,333,770 3,393,167 3,291,369 11.42 
40-44 3,754,485 3,846,979 3,792,642 3,836,540 3,853,588 3,818,217 3,764,295 3,810,279 3,717,279 12.09 
45-49 3,247,610 3,336,704 3,357,882 3,448,739 3,543,271 3,617,283 3,711,115 3,749,433 3,796,563 11.24 
50-54 2,768,381 2,847,564 2,815,610 2,873,622 2,982,492 3,072,667 3,195,213 3,255,673 3,339,159 9.60 
55-59 2,136,423 2,270,491 2,312,280 2,429,176 2,517,530 2,602,010 2,692,012 2,725,311 2,779,112 7.94 
60-64 1,640,010 1,666,310 1,658,030 1,749,639 1,867,292 2,018,386 2,205,744 2,261,073 2,373,041 6.16 
65-69 1,439,750 1,440,314 1,425,979 1,430,170 1,459,139 1,482,657 1,545,203 1,554,247 1,633,569 4.74 
70-74 1,086,790 1,117,640 1,091,743 1,133,569 1,180,408 1,219,016 1,266,427 1,269,010 1,261,197 3.76 
75-79 722,991 725,753 724,144 756,237 808,702 843,941 915,930 909,758 931,894 2.59 
80-84 406,112 404,181 395,234 427,276 463,313 501,880 556,589 552,467 561,637 1.51 
85-89 221,151 208,110 201,662 211,995 227,994 239,342 273,002 263,901 273,429 0.75 
Total 30,752,229 30,965,637 30,415,630 30,608,961 31,185,117 31,619,735 31,980,118 32,600,568 32,759,844 100.00 














































2005 2007 2009 2011 2013
Year
95% CI Fitted values
Rate

















6.3.2.2 Age-period-cohort analysis 


















































































































































































Model Effect Da/  Db/ p value 
1. Age - 10765.1 (828) Reference Reference 
2. Age-drift  |A c/ 2069.5   (827) 8695.6 0.001 
3. Age-Period P|A d/ 1889.8   (816) 179.7 0.001 
4. Age-Period-Cohort C|A,P e/ 374.0     (670) 1515.8 0.001 
5. Age-Cohort P|A,C f/ 597.7     (680) -223.7 0.001 
6. Age-drift C|A g/ 2069.5   (827) -1489.8 0.001 
a/ Residual deviance 
b/ Increase in residual deviance from the next upper model   
c/ Linear effect of cohort or period adjusted for age 
d/ Non-linear cohort effect adjusted for age 
e/ Non-linear period effect adjusted for age and cohort 
f/ Non-linear cohort effect adjusted for age and period  
g/ Non-linear period effect adjusted for age	















17 Risk ratio for the death outcome is also known as relative risk. It is the risk of an event (eg. death and 
registration) in a particular year in comparison to the reference year, and can be calculated by the rate in that 
particular year divided by the rate in the reference year. 





Note: Figure a shows estimated ESRD mortality rates by age in 2010 and Figure b shows mortality rate ratios 
(relative difference measure of mortality rate in any particular year divided by rate in the reference year-2010) 
for calendar years of death. Shaded areas are 95% confidence intervals. 
6.3.3 Case fatality rate (CFR) 







Age 2008 2009 2010 2011 2012 2013 %Total 
20-24 433 537 741 1,033 1,207 1,333 1.63 
25-29 630 803 1,098 1,480 1,708 1,785 2.35 
30-34 968 1,219 1,664 2,193 2,496 2,673 3.52 
35-39 1,241 1,511 2,076 2,767 3,201 3,433 4.44 
40-44 1,707 2,019 2,806 3,711 4,230 4,756 5.96 
45-49 2,317 2,705 3,749 5,162 5,858 6,620 8.15 
50-54 3,264 3,536 5,079 6,812 7,700 8,696 10.86 
55-59 3,831 4,076 5,821 7,946 8,994 10,467 12.62 





































2005 2006 2007 2008 2009 2010 2011 2012 2013
Calendar year of death
b. Rate ratios relative to the reference year(2010)
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Age 2008 2009 2010 2011 2012 2013 %Total 
65-69 3,863 3,938 5,571 7,507 8,231 9,675 11.98 
70-74 3,758 3,804 5,429 7,291 7,882 9,084 11.59 
75-79 2,736 2,704 3,961 5,383 5,745 6,727 8.45 
80-84 1,345 1,353 1,966 2,718 2,873 3,478 4.22 
85-89 477 468 758 1,046 1,043 1,242 1.56 

















Note: Rates were percentages of all-cause death counts of UCS patients diagnosed with ESRD divided by numbers 
of all UCS patients diagnosed with ESRD. Rates are presented by age at death, calendar year, and year of birth. 












































































































Note: Figures show estimated case fatality rate by age in 2010 (a) and case fatality rate ratio (relative difference 
measure of fatality rate in any particular year divided by rate in the reference year-2010) in 2008-2013 (b).    





Age RRT 2008 2009 2010 2011 2012 2013 Total %Total 
20-24 HD            2           4          6             5           6           6      159  1.1% 
PD            7         17         17           25         31        25  
KT          -             -           1             3           2           2  
25-29 HD            3         13          5             9         12           5          235  1.6% 
PD            9         24         39           33         43         36  
KT          -             -             -              3           1            -   
30-34 HD            5          9        14           16         21         11     
292  
2.0% 
PD            6         23        45           35         62        44  
KT          -             -             -             -             -            1  
35-39 HD            3         12         23           25         32         12       350  2.3% 
PD            9         34         42           48         59        50  
KT          -             -             -             -           1            -   
40-44 HD          11        29         27           31        46         24          616  4.1% 
PD          14        53        74           98      118        86  
KT          -             -              1             1             2             1  





















2008 2009 2010 2011 2012 2013Calendar year of death
b. Rate ratios relative to the reference year (2010)
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Age RRT 2008 2009 2010 2011 2012 2013 Total %Total 
PD          29         83       138          160       205       156  
KT          -             -           3             1            -            1  
50-54 HD          26         95         77           88        96         74       1,590  10.6% 
PD          28       111      189          249      294      252  
KT          -             -             -              1          6          4  
55-59 HD          25      106     105          151      170        97    2,121  14.2% 
PD          26       144       222          350      413       299  
KT          -            1          3             2          3          4  
60-64 HD          23      125      137          191      222      147       2,394  16.0% 
PD          19         96       278          347       448      345  
KT          -             -           3             4          4           5  
65-69 HD          33      147      161          193      243      136      2,198  14.7% 
PD            4        90       189          275      404       314  
KT          -            1          2             2          2           2  
70-74 HD          23       137      148          206      226       136       1,903 12.7% 
PD            5        57      169          243       315       233  
KT          -             -            2             1          2            -   
75-79 HD          25       129      106          138      190      111      1,266 8.5% 
PD            2         36         80          135       198       116  
KT  N/A   N/A   N/A   N/A   N/A   N/A  
80-84 HD 11 35 69 86 105 46 575 3.8% 
PD 1 16 27 63 72 44 
KT N/A N/A N/A N/A N/A N/A 
85-89 HD 6 18 26 37 50 28 226 1.5% 
PD - 5 5 22 18 11 
KT N/A N/A N/A N/A N/A N/A 
Total  363 1,693   2,478      3,342  4,192    2,905     14,973   100.0% 






Age 2008 2009 2010 2011 2012 2013 %Total 
20-24 174 290 388 501 603 657 2.7 
25-29 187 339 458 583 683 753 3.2 
30-34 217 424 617 783 886 1,000 4.1 
35-39 358 579 800 1,069 1,241 1,421 5.8 
40-44 513 825 1,176 1,513 1,759 2,025 8.2 
45-49 661 1,082 1,553 2,090 2,420 2,735 11.1 
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Age 2008 2009 2010 2011 2012 2013 %Total 
50-54 909 1,326 1,906 2,529 2,931 3,286 13.6 
55-59 1,002 1,481 2,156 2,785 3,200 3,694 15.1 
60-64 968 1,387 1,992 2,647 3,034 3,476 14.2 
65-69 926 1,145 1,538 1,998 2,148 2,361 10.6 
70-74 739 807 1,066 1,280 1,292 1,396 6.9 
75-79 424 392 477 589 525 573 3.1 
80-84 188 182 199 209 182 180 1.2 
85-89 44 43 46 33 19 9 0.2 






























2008 2009 2010 2011 2012 2013
Year
95% CI Fitted values
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Note: Estimated mortality rate for RRT patients by age in 2010 (a) and mortality rate ratio (relative difference 
measure of mortality rate in any particular year divided by rate in the reference year-2010) in 2008-2013 (b). 






















































2008 2009 2010 2011 2012 2013
Calendar year of death
b. Rate ratios relative to the reference year (2010)





























18 The denominator used for this rate was the entire UCS population including patients under 20 years old. 
When population aged less than 20 years were excluded from the denominator, the incidence rate was 293 pmp.   
19 Using the UCS population in 2013 as the reference population	





RRT= renal replacement therapy 
6.4 Discussion 
























































UCS RRT Relative Risk
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6.4.2 Summary of findings 




























































20 for the treatment of anemia of ESRD patients 


































21 of all 3 public schemes and all over the country 












Note: adjusted from the rate ratio graphs of registration into the RRT programme and mortality.  


































22	eGFR levels lower than 10ml/min/1.73m2 






























Age 2008 2009 2010 2011 2012 2013 
20-24 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 
25-29 0.02% 0.01% 0.02% 0.02% 0.01% 0.01% 
30-34 0.03% 0.01% 0.02% 0.02% 0.02% 0.01% 
35-39 0.03% 0.01% 0.02% 0.03% 0.02% 0.01% 
40-44 0.05% 0.02% 0.03% 0.04% 0.03% 0.02% 
45-49 0.07% 0.03% 0.05% 0.06% 0.05% 0.03% 
50-54 0.13% 0.05% 0.09% 0.09% 0.08% 0.05% 
55-59 0.18% 0.07% 0.13% 0.14% 0.14% 0.09% 
60-64 0.25% 0.10% 0.19% 0.20% 0.19% 0.12% 
65-69 0.32% 0.13% 0.25% 0.28% 0.27% 0.17% 
70-74 0.40% 0.16% 0.32% 0.37% 0.35% 0.20% 
75-79 0.46% 0.19% 0.39% 0.44% 0.42% 0.26% 
80-84 0.42% 0.19% 0.40% 0.45% 0.48% 0.29% 
85-89 0.31% 0.18% 0.36% 0.41% 0.46% 0.27% 
Total 0.11% 0.05% 0.09% 0.11% 0.10% 0.06% 









24	CFR= Number of deaths from all causes among patients with ESRD x 100/ Number of all patients with ESRD	





Age 2008 2009 2010 2011 2012 2013 
20-24 51.0% 145.2% 83.8% 78.9% 100.0% 100.0% 
25-29 36.5% 61.8% 46.8% 45.8% 60.7% 88.5% 
30-34 32.3% 48.9% 46.4% 39.9% 54.4% 92.4% 
35-39 32.1% 53.4% 41.9% 44.3% 49.6% 85.2% 
40-44 31.1% 52.7% 42.5% 38.8% 50.0% 79.1% 
45-49 28.7% 50.0% 39.6% 38.6% 49.8% 73.3% 
50-54 27.1% 45.3% 35.3% 36.0% 43.0% 68.2% 
55-59 24.7% 39.7% 32.7% 33.7% 37.8% 63.6% 
60-64 23.1% 33.6% 28.4% 29.3% 33.7% 55.3% 
65-69 21.0% 23.6% 20.9% 22.8% 25.7% 41.7% 
70-74 16.8% 14.4% 15.7% 15.5% 16.8% 31.8% 
75-79 13.1% 9.0% 8.4% 10.2% 10.8% 18.8% 
80-84 11.3% 5.2% 5.8% 6.7% 7.2% 9.0% 
85-89 8.8% 2.6% 4.2% 4.4% 4.2% 4.8% 
Total 22.8% 31.7% 25.1% 25.3% 28.8% 47.3% 
Note: bold figures represented relatively constant or low increasing percentages of elderly in comparison to 
overall UCS population, 2010-2012 















25 Proteinuria and serum creatinine 

















Age group Thai population 2004(%)1/ UC population 2010(%)2/ 
15-29 0 0.03 
30-44 0.2 0.06 
45-59 0.2 0.16 
>60 0.5 0.37 
Overall 0.2 0.14 
1/Prevalence of chronic kidney disease in Thai adults: a national health survey (Ong-ajyooth, 
Vareesangthip et al. 2009) 
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CHAPTER 7 Long term projections of RRT patients and costs 






























































26Total UCS budget including salary was 154,285 mBaht. Total spending on claims of the RRT programme was 
6,023 mBaht. 
































27 For example, PD differenced series at time t=PDt - PD(t-1) 



















Jan2009 1,232 6,271 39 7,638 130 -86 7
Feb2009 1,429 6,280 47 7,881 197 9 8
Mar2009 1,621 6,240 56 8,056 192 -40 9
Apr2009 1,849 6,215 99 8,387 228 -25 43
May2009 2,054 6,170 116 8,591 205 -45 17
Jun2009 2,296 6,134 127 8,826 242 -36 11
Jul2009 2,533 6,083 148 9,068 237 -51 21
Aug2009 2,741 6,046 162 9,270 208 -37 14
Sep2009 2,976 5,978 178 9,464 235 -68 16
Oct2009 3,204 6,008 190 9,746 228 30 12
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PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant 









































(i)  Service bundle 
 PD  
 HD  
 Transplantation 
(ii) Medicine and medical device 
 For PD: fluids, catheters, EPO 
 For HD: EPO  
 For KT: IS in the first year 
 
(iii)  Additional reimbursements 
 For PD: temporary HD 
 For HD: vascular access 
            : EPO for self-pay HD 
 For KT: IS in subsequent 
years 






































ܶ݋ݐ݈ܽ	݌ܽݕ݉݁݊ݐ	݌݁ݎ	ݕ݁ܽݎ	 ൌ 		ݐ݋ݐ݈ܽ	݋݂	ሺ݊ݑܾ݉݁ݎ	݋݂	݈ܿܽ݅݉ݏ ∗ ݎܾ݁݅݉ݑݎݏ݁݉݁݊ݐ	ݎܽݐ݁ሻ	
ܷ݊݅ݐ	ܿ݋ݏݐ		 ൌ 			 ݐ݋ݐ݈ܽ	݌ܽݕ݉݁݊ݐ	݌݁ݎ	ݕ݁ܽݎݐ݋ݐ݈ܽ	ܭܶ	݋݌݁ݎܽݐ݅݋݊ݏ 	
































































II. Estimating unit cost from the payer’s perspective
Multiply with payment rate
	
PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant,  
TK= Tenckhoff catheter, EPO=erythropoietin, IS=immunosuppressive drugs, 
MC=material costs, LC=labour costs, CC=capital costs 










7.2.3.1 Future scenarios 
It	is	possible	that	the	unit	cost	will,	in	the	next	ten	years,	deviate	from	what	it	
was	in	2014.	Chapter	5	provided	insights	into	what	future	scenarios	could	be,	









Scenario Material cost Labour cost Capital cost 
1   
2   
3   













































































28 Meaning patients who had transplantation by self-financing or other means before the start of the RRT 
programme in 2008.	These patients are supported with free EPO by the NHSO.  





    
   1/cost per patient of the third group (see Table 7-2), 2/ unit cost per patient of the second group (see Table 7-2) 












































2008m1 2010m1 2012m1 2014m1
Time
PD HD total dialysis
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pd=peritoneal dialysis, Dpd=differenced series 





























































































































hd=hemodialysis, Dhd=differenced series of hemodialysis 























































































































kt=kindey transplant, Dkt=differenced series of kidney transplant 




Ŷt  =  μ + Yt-1 – θ1et-1 





























































































































Ŷt    =   μ + Yt-1 + φ (Yt-1 - Yt-2) 
































































































































































































Upper limit Lower limit
Figure 7‐8		Actual and predicted PD, HD, and KT patients to the year 2024 












Year PD HD KT Total 
2014      14,327   12,132          960     27,420  
2015      16,336   13,888       1,102     31,326  
2016      18,346   15,644       1,243     35,233  
2017      20,355   17,399       1,385     39,139  
2018      22,364   19,155       1,526     43,046  
2019      24,373   20,911       1,668     46,953  
2020      26,383   22,667       1,809     50,859  
2021      28,392   24,423       1,951     54,766  
2022      30,401   26,179       2,092     58,672  
2023      32,410   27,935       2,234     62,579  
% average annual growth rate 10.2 12.5 10.6 10.3 
PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant 
7.3.2 Costs of the RRT programme 















Activity Reimbursement Average use payment/patientyear 
Temporary HD* 1,500 Baht/session 7.45 sessions N/A 
PD service 2,500 Baht/month 12 times/year 30,000 
PD solution (bag) 120 Baht/bag** 1,460 bags/year 175,200 
EPO 200 Baht/vial** 72.43 vials/year 14,486 
EPO administration 50 Baht/time 47.34 times/year 2,367 
Tenckhoff catheter 4,172 Baht/catheter** 0.59 catheters/year 2,461 
Total (Baht)   224,514 
HD=hemodialysis, PD=peritoneal dialysis, EPO=erythropoietin 
*Temporary HD was classified as additional cost to the NHSO and excluded in the unit cost per patient-year  
  calculation 
**Prices that NHSO purchased in 2014 















29 The amount was calculated from the total claim cost of HD sessions divided by the total number of claims 




Activity Reimbursement Average use Payment/patientyear 
Vascular access* 5,000-12,000 Bath/operation 1 time N/A 
HD session 1,529.34 Bath/session** 131.65 times/patient-year 201,344 
EPO 200 Baht/vial 77.55 vials/patient-year 15,510 
EPO administration 50 Bath/time 45.56 times/patient-year 2,278 
Total (Bath)  General HD  
Self-pay HD 
219,132   
17,788 
HD=hemodialysis, EPO=erythropoietin 
*Vascular access was classified as additional cost to the NHSO and excluded in the unit cost per patient-year  
  calculation,  
**Calculated from total claims costs divided by total number of claims 








Activity Total payment 
Living donor pre-operation and nephrectomy  27,200,300  
Deceased donor nephrectomy       9,300,300  
Recipient’s transplant programme30      39,421,280  
Kidney transplant operation 
      Protocol 1  
      Protocol 2  
      Protocol 3  
      Protocol 4 
      5,788,900  
      12,216,500  
      2,928,000  
     38,190,680	 
Transplant with complications 
      ARC_A 
      ARC_B 






30 Including panel reactive antibody, an immunological laboratory test routinely performed on the blood of people 
awaiting transplantation 
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Activity Total payment 
      AMR_B 
      DGF_A 
      DGF_B 





Total payment  to 183 operations 175,735,560 








 Reimbursement Total payment/patient-year 
IS in first 1-6 months 30,000/month 
330,000   IS in next 7-12 months 25,000/month 
IS in next 13-24 months 20,000/month 240,000   













31 Medications here assumed to include both items that were purchased in bulk quantities at the central NHSO 
then allocated to hospitals and items that hospitals bought by themselves. 








 PD (%) HD (%) KT (%) 
Material cost        216,099 (96)         103,068 (47) 467,931 (46) 
Labour cost          8,092 (4)         81,449 (37)  172,855 (38)  
Capital cost            324 (<1)         34,616 (16)  28,809  (16)  
     Total cost       224,514 (100)        219,132 (100)        1,290,304*(100)  
PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant 
*Figure represents costs for donor nephrectomy, recipient’s transplant programme, PRA test, transplantation 





















PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant 
7.3.3 Future budget needs of RRT programme 









Year PD HD KT Total 
2014 3,239 2,773 411 6,422 
2015 3,700 3,195 439 7,334 
2016 4,164 3,649 467 8,280 
2017 4,632 4,137 494 9,263 
2018 5,104 4,660 522 10,286 
2019 5,581 5,227 550 11,358 
2020 6,063 5,835 578 12,476 
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Year PD HD KT Total 
2022 7,046 7,226 635 14,907 
2023 7,547 8,009 664 16,220 
% average annual 
growth rate 10 13 6 11 
PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant 
Note: numbers were rounded to the nearest million, in terms of 2014-constant Baht 










Year PD HD KT Total 
2014 3,239 2,770 411 6,420 
2015 4,054 3,343 480 7,877 
2016 4,999 4,004 557 9,560 
2017 6,091 4,760 646 11,497 
2018 7,351 5,623 747 13,721 
2019 8,803 6,611 861 16,275 
2020 10,469 7,732 991 19,192 
2021 12,381 9,017 1,138 22,535 
2022 14,570 10,474 1,305 26,349 
2023 17,071 12,126 1,494 30,691 
% average annual 
growth rate 
20 18 15 19 
PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant 
Note: numbers were rounded to the nearest million, in terms of 2014-constant Baht 
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Year PD HD KT Total 
2014 3,239 2,770 411 6,420 
2015 2,992 2,889 357 6,238 
2016 3,369 3,304 380 7,053 
2017 3,750 3,753 402 7,906 
2018 4,135 4,237 425 8,798 
2019 4,526 4,766 448 9,739 
2020 4,921 5,335 471 10,727 
2021 5,322 5,964 494 11,780 
2022 5,730 6,648 518 12,896 
2023 6,144 7,393 542 14,078 
% average annual 
growth rate 8 12 3 9 
PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant 














S1=scenario 1, S2=scenario 2, S3=scenario 3, PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant 





















































S1=scenario 1, S2=scenario 2, S3=scenario 3 





























































































































































































32 Old transplant cases were assumed that they have exited from the system and were not included in the 
denominator, unlike PD and HD that denominators were cumulative cases. 
33 http://www.kidneythai.org/newsdetail30.php 
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 PD HD KT 
Thailand (current study)* 7,242 6,968 30,009 
Mexico (2013)** 8,695 N/A N/A 
Brazil (2013)**  23,404 23,411 N/A 
India (2012, 2013)*** 6,275 6,382 Up to 12,924 
*Figures were calculated from the payer’s perspective 
** Figures were calculated from the provider’s perspective including medical costs and professional fees 
excluding costs for emergency visits and hospitalisation 
***Costs for out-of-pocket payment 
Sources: Mexico: Cortés-Sanabria, Paredes-Cesena et al. (2013); Brazil: de Abreu, Walker et al. (2013); India: 

















































i. Internal validity: long term effect 
The	advantage	of	the	time‐series	approach	is	that	it	can	eliminate	the	effects	of	
other	factors	that	may	influence	the	variable	of	interest.	However,	the	approach	





ii. External validity: generalisability 
Since	the	RRT	programme	is	designed	to	serve	a	specific	population,	the	result	
is	not	meant	to	explain	or	be	used	in	other	groups	of	patients.	
























CHAPTER 8  Discussion  
243 
	







































































































































































































































































































































CHAPTER 8  Discussion  
253 
	




































































































































34 a kidney function indicator 
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iv. Routine reporting system and ongoing process/outcomes 























v. Self-care management and educational programmes that may 
include raising awareness of secondary prevention, adherence to 
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Appendix 1 EMBASE search results   
No. Terms Number retrieved 
1 "disease management".ti,ab. 13,216  
2 effect$.ti,ab. 6,600,707 
3 nation$.ti,ab. 544,626 
4 region$.ti,ab. 1,487,746 
5 sickness fund.ti,ab. 226  
6 decentral$.ti,ab. 6,866  
7  (county or counties).ti,ab. 59,065 
8 countr$.ti,ab. 378,593 
9 3 or 4 or 5 or 6 or 7 or 8 2,314,026 
10 1 and 2 and 9 923  
11 limit 10 to (abstracts and english language and yr="2003 - 2015") 768 
Appendix 2 Interview questions for policy makers and health care 
providers 
Main question Additional question 
I. general questions 
1. What are your job 
descriptions/responsibilities? 
• How many year you’ve been working on this job? 
II. High cost disease 
2. From your experience, have you ever seen a 
patient who paid for health care until 
bankrupted 
• What kind of disease the patient had, general 
disease(s) or chronic disease(s)? 
• What was the main reason? 
3. In your opinion, what are the characteristics 
of a disease that can cause the patient 
bankrupt? 
• Before the existing of NHSO and after NHSO, are 
they different? 
III. Disease management of RRT programme 
4. How do you diagnose a patient having last 
stage of chronic kidney disease 
(ICD10=N185)? 
• In the case that you or the patient does not want to 
start a dialysis at the moment, how do you diagnose 
that patient? 
5. How about the referral system?  • From community hospital to higher level 
• From health centre to community hospital 
6. How do you manage the HR for the PD first 
programme) 
• How many nephrologist, GPs, nurses, and patients 
you have? 
7. In your opinion, what are advantages and 
disadvantages of separating the RRT 
programme from other treatments which are 
paid by capitation payment. 
• Increase access to high cost treatment? 
• (keyword: Patient identification, payment, guideline 
protocol    
8. What about the reporting system?  







IV. Holistic care/ palliative care  
9. Do you offer both holistic care/ palliative care 
to CKD patients? 
• What kind of activities you have? 
• Can you describe the flow/patient journey? 
• Do patients who have dialysis and patients who 
choose conservative therapy (no RRT) receive the 
same palliative care?  
10. In what stage that a patient can deny RRT • Generally, who is the one who makes decision 
(GP/nurse/patient/family) 
11. How do you evaluate a patient and get him 
ready for the conservative therapy? 
• Are there any processes of counseling and asking 
patient’s feedback?  
  
12. From the beginning of the RRT programme, 
what changing pattern do you observe?  
• Eg. No of patients on PD in comparison to HD and KT 
• Withdrawal and refusal of RRT in the first place 
• Effects of new policies  
13. Quality of life of ESRD patients  • Dialysis/KT/conservative patients 
14. Community supports  
IV. Opinion on RRT programme 
Main question Additional question 
1. Ask general questions about … • Age, place of birth, career, source of income, 
education, history of illness, and carer 
2. How did you about your condition (ESRD)? • When was that and who told you? 
• Were you worried, what about? 
• How did you cope with the condition? 
3. Before that have you got screening tests? • In which hospital, how and by who? 
4. After you know about your condition, what 
happen then? 
• What did you/family think? 
• Did you go to receive the treatment? 
5. Could you tell about the decision making 
process? 
• Did you/family have an opportunity to make 
decision about your treatment? 
• Did you know ‘PD first’? 
6.  (If received treatment) when did you register 
with the programme? 
• Did it take long to start the treatment? 
• How about your treatment? 
• How do you come to the hospital, how often, and 
anyone come along? 
• Are there any things you have to pay from your 
pocket? 
• Have you experienced a complication? 
7. (If not received treatment) what is the main 
reason of denying the treatment? 
• Who made the decision, you/family/doctor? 
• Did doctors give you enough information? 
• Is there any form of support you are given? 
8. How about your quality of life at the moment?  
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Appendix 3 Observation checklist 
Name:   Address:                         Date of collection: 
1.  Socio-economic information 
Age  
Sex  Male            Female 
Birthplace (Province) 
Marital status  Married        Single         Widow/separate 
Highest education  Primary or lower    Secondary     Bachelor’s or higher  
Career        
Household size                          Person(s) 
Household income                          Baht/month 
Main carer   
2.  History of illness 
Month/year diagnosed with ESRD  
Month/year starting dialysis    
Complication(s) from dialysis  No             Yes, …………………….. 
Comorbidity(ies)  
3.  Features of the house 
House type 
 House    Flat     Other 
Patient’s bedroom 
Own bedroom?         Yes                   No 
Good air flow?          Yes                    No  
Cleanliness?             Conform            Not conform 
House’s perimeter 
Cleanliness?             Conform            Not conform               
Hygiene?                  Conform            Not conform               
Pet?     No             Yes, kept away from exchange area   
                                 Yes, kept near exchange area   
Water source 
 Tap water      Ground water      Rain water       Other 
Exchange area 
Have a separate room?     Yes                  No 
Cleanliness?                       Conform         Not conform               
Stock of dialysis bags 
Separate area?        Yes              No 
Good air flow?          Yes             No  
Direct sunlight          Yes             No 
Cleanliness?            Conform      Not conform               





4. Changing practice 
1) General information 
How often do you do exchange?   
How do you get dialysis bags?   Srinagarind hospital    Health centre  		 Home delivery 
Normally, who do the changing?    Yourself                      Carer 
2) Equipment 
1. Table/ flat surface  Have            Don’t have 
2. Liquid soap  Have            Don’t have 
3. Alcohol  Have            Don’t have 
4. Hand towel  Have            Don’t have 
5. Cotton ball  Have            Don’t have 
6. Water resistance, adhesive bandage  Have            Don’t have 
7. Hook/pole with hook  Have            Don’t have 
8. Hanging scale  Have            Don’t have 
9. Bucket to place empty bag in  Have            Don’t have 
10. Bucket to place used hand towel in  Have            Don’t have 
11. Sink with single lever faucet  Have            Don’t have 
3) Exchange technique 
1. Arranging equipment  Correct          Incorrect 
2. Hand washing  Correct          Incorrect 
3. Surface cleaning  Correct          Incorrect 
4. Checking the unused bag  Correct          Incorrect 
5. Combining and connecting exchange devices  Correct          Incorrect 
6. Weighing of used dialysis solution  Correct          Incorrect 
7. Updating health records  Correct          Incorrect 
8. Waste disposal  Correct          Incorrect 
9. Arranging equipment  Correct          Incorrect 
10. Hand washing  Correct          Incorrect 
11. Surface cleaning  Correct          Incorrect 
12. Checking the unused bag  Correct          Incorrect 
13. Combining and connecting exchange devices  Correct          Incorrect 
5. Exit site  
Cleanliness   Clean            Infected 
Dressing technique  Correct          Incorrect 
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Appendix 4 Coding framework 
Root code Sub code 
High-cost disease View on high-cost disease 
 Coping high-cost disease 
Chronic renal failure  Reason to select chronic renal failure to manage 
 Reason to separate from other diseases 
 How to select disease 
HR HR allocation knowledge 
 View on HR allocation 
Payment Reimbursement knowledge 
 Motivation from payment 
 View on payment 
Protocol Guideline/protocol knowledge 
 View on guideline/protocol 
Reporting/M&E Report, M&E knowledge 
 View on report, M&E 
Collaboration practice Provider-patientpractice 
 Purchaser-providerpractice 
 View on collaborative practice  
Family/community support View on family support 
 View on community support 
Patient journey Patient journey knowledge 
Patient characteristics Demographic 
 Socio-economic 
 Beliefs 
Patients’ decision making Reasons 
 By whom  
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Appendix 6 Research articles conducted to advocate including the RRT 
benefit in the UCS  
Dimension Aim Type/Method 
Results 




To raise the 
importance of the 
problem  
Review articleof 
situations in Thailand 
and other countries 
Access to RRT was limited only to those 
who were well-off, at around 23% of all 
ESRD patients  
2. Access to RRT 
(Tangcharoensathien, 
Teerawattananon et al. 
2001) 
To give possibilities 
of including RRT 
benefit into the UCS 
Policy analysis There is a need to take action on planning 
of service provision of RRT(including 
resources:HR/unit/budget), as well as 
programme expenditure 
3. Cost-effectiveness of 
RRT(Chewchanwattana, 
limwattananon et al. 
2003) 
To compared costs of 
2 mode of dialysis 
(HD and CAPD) 
Cost-utility analysis Using secondary data input from the US. 
renal data system (2002), ICER of CAPD in 





of the RRT(Krairittichai, 
Supaporn et al. 2003) 
To report current 
situations regarding 
infrastructures of the 
RRT 
Annual report of TRT 
registry 
Thailand Registry of Renal Replacement 
Therapy started its mission in 1997. Until 
2003 there were201 registered RRT units. 
Incidence and prevalence of ESRD in 2001 
were 23.4 and 112.7 pmp respectively. 
5. Cost-effectiveness of 
RRT (Teerawatananon 
2006) 
To compared costs of 
2 mode of dialysis 
(HD and CAPD) and 
without  treatment  
Cost-utility analysis CAPD had more cost-benefit 
and(Kasemsap, Teerawatananon et al. 
2006) cost-utility in comparison to HD in all 
age groups. Both dialysis modes were not 
cost-effectiveness when using GDP or 3 
times GDP as indicators. 
6. Demand of the 
programme (Kasemsap, 
Teerawatananon et al. 
2006) 
To estimate numbers 
of patients who need 
to use RRT 
Calculations of 
incidence rate and 
survival rate 
Under the circumstance of every ESRD 
patients can use RRT, there were 14,000 
patients in 2005, would increase to 50,000 
in 2009. 
7. Public opinion 
(Tangcharoensathien, 
Vasavid et al. 2006) 
To seek opinion from 
the public regarding 
the RRT benefit of 
the UCS 
Descriptive analysis 
of the survey 
Most Thais supported including the RRT 
benefit into the UCS. Just half of 
respondent agreed about paying a small 
amount of contribution (of less than 800  
Baht -approx.₤17-per month) 
8. Budget impact 
(Kasemsap, Prakongsai 
et al. 2006) 




Budget estimate In the first year of the programme, it would 
require 4,000-6,500 mBaht/year. These 
amounts would increase to more than 
50,000mBaht/year in the 14th year. 











Including the RRT benefit into the UCS was 
essential to protect its beneficiaries from 
financial catastrophic due to service costs. 
Prioritising to those with more health needs 
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might help sustain the programme.  
10. Economic impact  
(Prakongsai, Palmer et 
al. 2009) 
To assessed impact 




In-depth interview Households spent 25%–68% of their total 
income for dialysis. All poor patients faced 
catastrophic health spending while well-off 
patients had adequate dialyses, therefore 
more survival rates and better quality of life. 
Note: RRT=renal replacement therapy, ESRD=end stage renal disease, CAPD=continuous ambulatory peritoneal dialysis, 
HD=hemodialysis, UCS=Universal Coverage Scheme, ICER=incremental cost-effectiveness ratio, QALY=quality-adjusted life 
year	
Appendix 7 Selected Stata commands for entry into the RRT programme 
(For hemodialysis) 
**CONSTRUCT ANALYTIC DATASETS 
use "ESRD_OPIP_HDPDKT_2008to2013r2",clear 
keep if rrt==1 




label variable A "Age at Registration" 
sort pid  
display _N 
keep C P A 
contract P A C 
rename _freq D 
label variable D "Number of HD registration" 
drop if A<20 
drop if A>89 
drop if P>2013 




replace ageRange=0 if A>=0&A<5 
replace ageRange=5 if A>=5&A<10 
replace ageRange=10 if A>=10&A<15 
replace ageRange=15 if A>=15&A<20 
replace ageRange=20 if A>=20&A<25 
replace ageRange=25 if A>=25&A<30 
replace ageRange=30 if A>=30&A<35 
replace ageRange=35 if A>=35&A<40 
replace ageRange=40 if A>=40&A<45 
replace ageRange=45 if A>=45&A<50 
replace ageRange=50 if A>=50&A<55 
replace ageRange=55 if A>=55&A<60 
replace ageRange=60 if A>=60&A<65 
replace ageRange=65 if A>=65&A<70 
replace ageRange=70 if A>=70&A<75 
replace ageRange=75 if A>=75&A<80 
replace ageRange=80 if A>=80&A<85 




replace CRange=1991 if C>=1991&C<1994 
replace CRange=1986 if C>=1986&C<1991 
replace CRange=1981 if C>=1981&C<1986 
replace CRange=1976 if C>=1976&C<1981 
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replace CRange=1971 if C>=1971&C<1976 
replace CRange=1966 if C>=1966&C<1971 
replace CRange=1961 if C>=1961&C<1966 
replace CRange=1956 if C>=1956&C<1961 
replace CRange=1951 if C>=1951&C<1956 
replace CRange=1946 if C>=1946&C<1951 
replace CRange=1941 if C>=1941&C<1946 
replace CRange=1936 if C>=1936&C<1941 
replace CRange=1931 if C>=1931&C<1936 
replace CRange=1926 if C>=1926&C<1931 
replace CRange=1921 if C>=1921&C<1926 




replace PRange=2005 if P>=2005&P<2006 
replace PRange=2006 if P>=2006&P<2007 
replace PRange=2007 if P>=2007&P<2008 
replace PRange=2008 if P>=2008&P<2009 
replace PRange=2009 if P>=2009&P<2010 
replace PRange=2010 if P>=2010&P<2011 
replace PRange=2011 if P>=2011&P<2012 
replace PRange=2012 if P>=2012&P<2013 
replace PRange=2013 if P>=2013&P<2014&P!=. 
tempfile x 
quietly save `x', replace 
 
*DESCRIPTIVE HD POPULATION 
use `x',clear 
keep D ageRange PRange 
egen pop=sum(D), by(PRange ageRange) 
label define ageRange 20"20-24" 25"25-29" 30"30-34" 35"35-39" 40"40-44" 
45"45-49" ///   
50"50-54" 55"55-59" 60"60-64" 65"65-69" 70"70-74" 75"75-79" 80"80-84" 
85"85-89"  
label value ageRange ageRange 
label variable ageRange "Age" 
contract pop ageRange PRange 
drop _freq 
rename ageRange Age 
rename PRange Year  
sort Year Age 
reshape wide pop, i(Age) j(Year) 
forvalue i=2008/2013 { 





poprisktime using popESRD_Allnewdata_r2, age(A) period(P) cohort(C) 
cases(D) /// 
agemin(20) agemax(89) permin(2008) permax(2013) missingreplace  
drop if Y==0 
drop if Y==. 
label variable Y "Poprisktime" 
 
*APC FIT: AP MODEL,REFERENCE PERIOD=2010,DF=5 
apcfit, age(A) period(P) cases(D) poprisktime(Y) nper(1000) refper(2010) 
param(AP) 
 
*CREATE GRAPH FOR AGE 
twoway (rarea agefitted_uci agefitted_lci A, sort pstyle(ci) color(orange) 
fintensity(inten50)) /// 
       (line agefitted A, sort lc(cranberry) clpattern(solid)) /// 
       , yscale(log)  name(A,replace) title("HD" "c.",position(11)) 
legend(off) /// 
         ylabel(2 5 10 20, angle(h)) xlabel(20(20)80) /// 
  Appendices  
310 
	
         xtitle("Age") ytitle("Rate per 1,000 ESRD diagnosis-years") 
scheme(sj) 
 
*CREATE GRAPH FOR PERIOD  
twoway (rarea perfitted_uci perfitted_lci P, sort pstyle(ci) 
color(eltgreen)  /// 
        fintensity(inten50)) (line perfitted P, sort lc(emerald) 
clpattern(solid)) /// 
        ,legend(off) name(P,replace) title(" " "d.",position(11)) /// 
        xtitle("Calendar Time") ytitle("Rate Ratio") yscale(log) /// 
  ylabel(1 2 4 15 50) xlabel(2009 2011 2013)  
*COMBINE AGE AND PERIOD GRAPHS 
graph combine A P, nocopies imargin(2 2 2 2) scheme(sj) ysize(4) xsize(8) 
name(hd,replace)   
 
 
**DESCRIPTIVE GRAPHS OF ACCESS TO HD (ESRD INCEDENCE AS DENOMINATOR) 
clear 
clear matrix 
set more off 
cd "D:\..." 
  
*CONSTRUCT ANALYTIC DATASETS 
use "ESRD_OPIP_HDPDKT_2008to2013r2",clear 
keep if rrt==1 




label variable A "Age at Registration" 
sort pid  
display _N 
keep C P A 
contract P A C 
rename _freq D 
label variable D "Number of HD registration" 
drop if A<20 
drop if A>89 
sort P A C 
tempfile a 




sort P A C 
merge 1:1 P A C using `a' 
keep if _merge==3 
drop _merge 
drop if P>2013 
display _N 
tempfile hd 
quietly save `hd', replace 
 
*1)GRAPHS RATE VS AGE BY PERIOD 
use `hd',clear 
egen Dpa=sum(D), by(P ageRange) 
egen Poppa=sum(pop), by(P ageRange) 
contract P ageRange Dpa Poppa  
drop _freq 
gen Rate=Dpa*100/Poppa 
format Rate %5.0f 
keep P ageRange Rate 
reshape wide Rate, i(ageRange) j(P) 
graph twoway (connected Rate* ageRange,sort name(HDdes1,replace) /// 
 title("Hemodialysis" "a",position(11)) /// 
 ytitle("Rate per 100 new ESRD diagnoses", margin(l=3 r=3)) /// 
 xtitle("Age at Registration") /// 
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 ylabel(0(10)30) xlabel(20(10)85) ytick(5(5)30) msymbol(O D T S Oh Dh 
Th Sh) /// 
 clwidth(medthick medthick medthick medthick medthick medthick 
medthick medthick medthick) /// 
 legend(label(1 "2008") label(2 "2009") label(3 "2010") label(4 
"2011") label(5 "2012") label(6 "2013")  /// 
  rows(4) colfirst subtitle("Calendar Year"))) 
 
*2)GRAPHS RATE VS AGE BY COHORT 
use `hd',clear 
egen Dca=sum(D), by(ageRange CRange) 
egen Popca=sum(pop), by(ageRange CRange) 
contract ageRange CRange Dca Popca  
drop _freq 
gen Rate=Dca*100/Popca 
format Rate %5.0f 
keep CRange ageRange Rate 
reshape wide Rate, i(ageRange) j(CRange) 
graph twoway (connected Rate* ageRange,sort name(HDdes2,replace) /// 
 title(" " "b",position(11)) /// 
 ytitle("Rate per 100 new ESRD diagnoses",margin(l=2 r=2)) xtitle("Age 
at Registration",margin(t=1 b=1)) /// 
 ylabel(0(10)30) xlabel(20(10)85) ytick(5(5)30) /// 
 msymbol(O D T S + Oh Dh Th Sh X o d t s p smplus)  /// 
 clwidth(medthick medthick medthick medthick medthick medthick 
medthick medthick medthick /// 
 medthick medthick medthick medthick medthick medthick medthick) /// 
 legend(label(1 "1916-20") label(2 "1921-25") label(3 "1926-30") 
label(4 "1931-35") /// 
  label(5 "1936-40") label(6 "1941-45") label(7 "1946-50") 
label(8 "1951-55") /// 
  label(9 "1956-60") label(10 "1961-65") label(11 "1966-70") 
label(12 "1971-75") /// 
  label(13 "1976-80") label(14 "1981-85") label(15 "1986-90") 
label(16 "1991-93") /// 
 rows(4) colfirst subtitle("Birth Year") symxsize(6)keygap(0))) 
  
*3)GRAPHS RATE VS PERIOD BY AGE 
use `hd',clear 
egen Dpa=sum(D), by(P ageRange) 
egen Poppa=sum(pop), by(P ageRange) 
contract P ageRange Dpa Poppa  
drop _freq 
gen Rate=Dpa*100/Poppa 
format Rate %5.0f 
keep P ageRange Rate 
reshape wide Rate, i(P) j(ageRange) 
graph twoway (connected Rate* P,sort name(HDdes3,replace) title(" " 
"c",position(11)) /// 
 ytitle("Rate per 100 new ESRD diagnoses", margin(l=3 r=5)) 
xtitle("Calendar Year",margin(t=1 b=1)) /// 
 ylabel(0(10)30) xlabel(2008(1)2013) ytick(5(5)30) /// 
 msymbol(O D T S + Oh Dh Th Sh X o d t s) /// 
 clwidth(medthick medthick medthick medthick medthick medthick 
medthick /// 
  medthick medthick medthick medthick medthick medthick 
medthick) /// 
 legend(label(1 "20-24") label(2 "25-29") label(3 "30-34") label(4 
"35-39") label(5 "40-44") /// 
  label(6 "44-49") label(7 "50-54") label(8 "55-59") label(9 
"60-64") label(10 "65-69") /// 
  label(11 "70-74") label(12 "75-79") label(13 "80-84") label(14 
"85-89") rows(4) colfirst /// 
  subtitle("Age at Registration") symxsize(9))) 
 
*4)GRAPHS RATE VS COHORT BY AGE 
use `hd',clear 
egen Dca=sum(D), by(CRange ageRange) 
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egen Popca=sum(pop), by(CRange ageRange) 
contract CRange ageRange Dca Popca  
drop _freq 
gen Rate=Dca*100/Popca 
format Rate %5.0f 
keep CRange ageRange Rate 
replace Rate=. if Rate==0 
reshape wide Rate, i(CRange) j(ageRange) 
graph twoway (connected Rate* CRange,sort name(HDdes4,replace) title(" " 
"d",position(11)) /// 
 ytitle("Rate per 100 new ESRD diagnoses",margin(l=2 r=2)) 
xtitle("Birth Year",margin(t=1 b=1)) /// 
 ylabel(0(10)30) xlabel(1915(10)1990) ytick(5(5)30) /// 
 msymbol(O D T S + Oh Dh Th Sh X o d t s) /// 
 clwidth(medthick medthick medthick medthick medthick medthick 
medthick /// 
  medthick medthick medthick medthick medthick medthick 
medthick) /// 
 legend(label(1 "20-24") label(2 "25-29") label(3 "30-34") label(4 
"35-39") label(5 "40-44") /// 
  label(6 "44-49") label(7 "50-54") label(8 "55-59") label(9 
"60-64") label(10 "65-69") /// 
  label(11 "70-74") label(12 "75-79") label(13 "80-84") label(14 
"85-89") rows(4) colfirst /// 
  subtitle("Age at Registration") symxsize(8) keygap(0)))  
 
*COMBINE 4 GRAPHS AND SAVE 
graph combine HDdes1 HDdes2 HDdes3 HDdes4,row(2) col(2) ycommon imargin(b=1 
t=1) iscale(.4) /// 
graphregion(margin(l=0 r=3)) ysize(11) xsize(8) 
 
 
Appendix 8 Test for unit root, serial correlations, white noise in the error 
terms, and AIC before differencing  
Test 
Model 
PD HD KT 
Dicky-Fuller * 0.804 0.244 0.824 
Durbin-Watson d-statistic** 0.057 0.110 0.061 
Durbin's alternative** <0.001 <0.001 <0.001 
Breusch-Godfrey LM** <0.001 <0.001 <0.001 
Portmanteau (Q) statistic*** <0.001 <0.001 <0.001 
AIC 1388.328 1345.492 1008.531 
*H0=No presence of a unit root 
**H0=no serial correlation 
***H0=No presence of a white noise 
Appendix 9 Test for unit root, serial correlations, white noise in the error 
terms, and AIC after first differencing 
Test 
Model 
PD HD KT 
Dicky-Fuller * <0.001   <0.001 <0.001 





PD HD KT 
Durbin-Watson d-statistic N/A N/A N/A 
Durbin's alternative** <0.001 0.266 <0.001 
Breusch-Godfrey LM** <0.001 0.263 <0.001 
Portmanteau (Q) statistic*** 0.999 1.000 0.982 
AIC 1163.646 1169.222 1171.975 
*H0=No presence of a unit root 
**H0=no serial correlation 
***H0=No presence of a white noise  
Appendix 10 Results from fitting ARIMA models 
PD  
------------------------------------------------------------------------------ 
             |                 OIM 
        D.pd |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
pd           | 
       _cons |   167.4371   48.15384     3.48   0.001     73.05733    261.8169 
-------------+---------------------------------------------------------------- 
ARMA         | 
          ma | 
         L1. |  -.4828109   .1099371    -4.39   0.000    -.6982837   -.2673381 
-------------+---------------------------------------------------------------- 




             |                 OIM 
        D.hd |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
hd           | 
       _cons |   146.3224   93.61479     1.56   0.118    -37.15922     329.804 
-------------+---------------------------------------------------------------- 
ARMA         | 
          ar | 
         L1. |  -.1310408   .1168015    -1.12   0.262    -.3599675    .0978858 
-------------+---------------------------------------------------------------- 




             |                 OIM 
        D.kt |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
kt           | 
       _cons |   11.79115   1.514517     7.79   0.000     8.822747    14.75955 
-------------+---------------------------------------------------------------- 
ARMA         | 
          ma | 
         L1. |  -.7633019   .1043864    -7.31   0.000    -.9678955   -.5587082 
-------------+---------------------------------------------------------------- 
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Bartlett's (B) statistic =     0.18   Prob > B = 1.0000
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Bartlett's (B) statistic =     0.33   Prob > B = 0.9999

























0.00 0.10 0.20 0.30 0.40 0.50Frequency
Bartlett's (B) statistic =     0.23   Prob > B = 1.0000
Cumulative Periodogram White-Noise Test
